Core Viewpoint - The company艾力斯 announced that its core product,甲磺酸伏美替尼片 (brand name "艾弗沙®"), has been included in the list of proposed breakthrough therapies by the National Medical Products Administration (NMPA) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) PACC mutations [1] Group 1 - The proposed indication for伏美替尼 is as a first-line treatment for specific NSCLC patients [1] - The public announcement period for this proposed breakthrough therapy is from December 25, 2025, to January 4, 2026 [1]

Core Viewpoint - The company emphasizes "innovation" as its core competitive advantage and is committed to an innovation-driven development strategy, aiming to expand its international product layout to benefit global patients [2] Group 1 - The company is actively promoting its internationalization strategy for innovative drugs [2] - The focus on innovation is central to the company's competitive strategy [2]

证券日报网讯12月19日，艾力斯在互动平台回答投资者提问时表示，随着伏美替尼一线及二线治疗适应 症进入国家医保报销范围，有效降低了患者的用药负担，进一步扩大了国内肺癌患者受益群体的数量。 此外，伏美替尼针对EGFR经典突变的辅助治疗适应症、20外显子插入突变一线及二线治疗适应症、 PACC突变的一线治疗适应症、针对EGFR敏感突变伴脑转移患者的治疗、EGFR非经典突变的辅助治疗 等均处于注册临床阶段，随着相关适应症在未来陆续获批，伏美替尼的市场空间会进一步扩大。对于耐 药患者的治疗，现有药物在疗效、安全性和可及性仍有进一步提升的空间。目前伏美替尼已经和c-MET ADC、TROP2/HER3ADC以及口服PD-L1抑制剂开展了联合用药临床研究，并得到了积极的初步疗效及 安全性数据，相关临床研究仍在持续推进中。 ...

Core Viewpoint - The stock of Ailis has shown significant growth this year, with a year-to-date increase of 72.55%, indicating strong market performance and investor interest [1]. Group 1: Stock Performance - As of December 19, Ailis's stock price reached 101.98 yuan per share, with a trading volume of 55.59 million yuan and a turnover rate of 0.12%, resulting in a total market capitalization of 45.891 billion yuan [1]. - In the past five trading days, the stock has increased by 2.86%, while it has seen a 6.80% rise over the last 20 days, but a decline of 5.13% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Ailis reported a revenue of 3.733 billion yuan, reflecting a year-on-year growth of 47.35%, and a net profit attributable to shareholders of 1.616 billion yuan, which is a 52.01% increase compared to the previous year [2]. Group 3: Shareholder and Institutional Holdings - As of September 30, 2025, the number of Ailis shareholders increased to 19,100, a rise of 46.82%, while the average number of circulating shares per person decreased by 31.89% to 23,551 shares [2]. - Ailis has distributed a total of 653 million yuan in dividends since its A-share listing [3]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fourth largest with 20.9471 million shares, an increase of 10.5693 million shares from the previous period [3].

Core Insights - The A-share market has shown a fluctuating upward trend since 2025, with the pharmaceutical and biotechnology sector performing exceptionally well, dominating the top ten stock fund rankings in the first half of the year [2] - Jin Xiaofei, a representative mid-generation fund manager at Penghua Fund, has achieved remarkable performance with his managed funds, utilizing a unique "dual-line resonance" framework to navigate crowded sectors [2][3] Investment Performance - Jin Xiaofei has been with Penghua Fund since July 2012, accumulating a tenure of 9 years and 174 days, managing assets totaling 5.375 billion yuan, with a best-term return of 239.59% [3] - The Penghua Medical Technology Stock A fund, under Jin's management, has shown significant excess returns, with a total return of 74.19% since its inception on June 2, 2015, and a return of 73.03% this year [5] - The Penghua Innovation Upgrade Mixed A fund has also performed well, with a year-to-date return of 88.72% and a one-year return of 74.60% [15] Investment Strategy - Jin's investment strategy is centered on "fundamental trend investing," integrating a dual-dimensional analysis framework that focuses on both visible driving factors and market sentiment [3][4] - The "bright line" strategy emphasizes significant industry changes, while the "dark line" strategy identifies undervalued opportunities through reverse analysis of market emotions and capital flows [4] - Jin's approach includes a three-dimensional decision-making framework that considers long-term, mid-term, and short-term performance metrics to ensure robust investment logic [14][16] Stock Holdings and Performance - The fund has made strategic purchases in various stocks, including: - 1,126,260 shares of Nuocheng Jianhua, which saw a price increase of 213% during the holding period [7] - 217,760 shares of Dizhe Pharmaceutical, with a price increase of 90.49% [9] - 119,040 shares of Baijishenzhou, which appreciated by 257% [11] - 211,230 shares of Rongchang Bio, with a price increase of 121% [13] - The fund's holdings in stocks like Hailan Pharmaceutical and Zexing Pharmaceutical also demonstrated significant price increases during their respective holding periods [18][20] Market Outlook - Jin Xiaofei anticipates a new investment cycle in the pharmaceutical sector, with institutional holdings recovering from historical lows, and emphasizes the importance of beta opportunities in the current market [5][16] - The need for continuous optimization of risk control systems is highlighted, as the industry faces increasing competition and innovation [25]

证券日报网讯 12月15日晚间，艾力斯发布公告称，2025年12月15日，公司召开了第三届董事会第二次 会议，审议通过了《关于使用部分暂时闲置募集资金进行现金管理的议案》。在保证不影响募集资金投 资项目实施、募集资金安全的前提下，公司及其全资子公司拟使用最高不超过人民币5.50亿元（含本 数）的暂时闲置募集资金进行现金管理，使用期限不超过12个月，期限内任一时点的交易金额（含投资 收益进行再投资的相关金额）不超过前述额度。在前述额度及期限范围内，公司可以循环滚动使用。本 事项无需提交公司股东会审批。 （文章来源：证券日报） ...

中信证券股份有限公司关于上海艾力斯医药科技股份有限公司 使用部分暂时闲置募集资金进行现金管理的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为上海艾 力斯医药科技股份有限公司（以下简称"艾力斯"或"公司"）首次公开发行股 票并上市的保荐人，根据《证券发行上市保荐业务管理办法》《上海证券交易所 科创板上市公司自律监管指引第 1 号——规范运作》《上市公司募集资金监管规 则》《上海证券交易所科创板股票上市规则》等相关法律、法规和规范性文件的 规定，对艾力斯使用部分闲置募集资金进行现金管理事项进行了核查，核查意见 如下： 一、募集资金基本情况 根据中国证券监督管理委员会出具的《关于同意上海艾力斯医药科技股份有 限公司首次公开发行股票注册的批复》（证监许可[2020]2559 号），公司向社会 公开发行人民币普通股 9,000 万股，每股发行价格为人民币 22.73 元，募集资金总 额为人民币 204,570.00 万元；扣除发行费用后实际募集资金净额为人民币 193,254.96 万元，其中，超募资金金额为人民币 42,986.71 万元。上述资金已全部 到位，经普华永道中天会计师事务所（特殊 ...

证券代码：688578 证券简称：艾力斯 公告编号：2025-035 上海艾力斯医药科技股份有限公司关于使用 部分暂时闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资种类：安全性高、流动性好、有保本约定的投资产品（包括但不 限于保本型理财产品、结构性存款、通知存款、定期存款、大额存单、协定 存款等） 投资金额：最高不超过人民币 5.50 亿元（含本数），使用期限自董事 会审议通过之日起 12 个月内有效，期限内任一时点的交易金额（含投资收益 进行再投资的相关金额）不超过前述额度。在前述额度及期限范围内，公司 可以循环滚动使用。 已履行审议程序：2025 年 12 月 15 日，上海艾力斯医药科技股份有限 公司（以下简称"公司"或"艾力斯"）召开了第三届董事会第二次会议， 审议通过了《关于使用部分暂时闲置募集资金进行现金管理的议案》，保荐 人中信证券股份有限公司对本事项出具了无异议的核查意见。本事项无需提 交公司股东会审批。 特别风险提示 本次现金管理方式是购买安全性高、流 ...

格隆汇12月15日丨艾力斯(688578.SH)公布，在保证不影响募集资金投资项目实施、募集资金安全的前 提下，公司及其全资子公司拟使用最高不超过人民币5.50亿元（含本数）的暂时闲置募集资金进行现金 管理，使用期限不超过12个月，期限内任一时点的交易金额（含投资收益进行再投资的相关金额）不超 过前述额度。在前述额度及期限范围内，公司可以循环滚动使用。 ...

Investment Rating - The report maintains an "Outperform" rating for several companies in the innovative drug and medical device industry, including Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical [5][6][25]. Core Insights - The report emphasizes the high prosperity in innovative drugs and continues to recommend companies with innovative pipelines that are entering a volume increase phase, maintaining "Outperform" ratings for various Biopharma/Biotech companies [5][25]. - The National Healthcare Security Administration announced the 2025 insurance drug list, which added 114 drugs, including 50 innovative drugs, further validating insurance support for innovation and indicating promising domestic demand [26][27]. Summary by Sections 1. Continuous Recommendation of Innovative Drugs and Industry Chain - The report highlights the ongoing recommendation of innovative drugs and the industry chain, with a focus on companies expected to see a revaluation due to their innovative pipelines [5][25]. - Specific companies mentioned include WuXi AppTec, WuXi XDC Cayman, Hangzhou Tigermed Consulting, and leading medical equipment companies like Beijing Chunlizhengda Medical Instruments and Lepu Medical, all rated "Outperform" [5][25]. 2. Performance of A-Shares Pharmaceutical Sector - In the second week of December 2025, the A-Shares pharmaceutical sector underperformed the market, with the SW Pharma and Biotech index falling by 1.0% compared to a 0.3% decline in the SHCOMP [8][27]. - The report notes that the premium level of the pharmaceutical sector relative to all A-Shares is at a normal level, with a current relative premium rate of 69.8% [16][27]. 3. Performance of Hong Kong and U.S. Pharmaceutical Sectors - The Hong Kong stock pharmaceutical sector underperformed the market, with the Hang Seng Healthcare index falling by 2.3%, while the U.S. stock pharmaceutical sector outperformed, with the S&P 500 Healthcare Select Sector Index rising by 0.4% [28][27].